Cornerstone Capital Management Holdings LLC. trimmed its position in EXACT Sciences Co. (NASDAQ:EXAS) by 6.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 42,261 shares of the medical research company’s stock after selling 2,900 shares during the period. Cornerstone Capital Management Holdings LLC.’s holdings in EXACT Sciences were worth $1,990,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the business. Advisor Group Inc. lifted its holdings in shares of EXACT Sciences by 0.8% during the 2nd quarter. Advisor Group Inc. now owns 7,866 shares of the medical research company’s stock worth $270,000 after acquiring an additional 65 shares during the last quarter. Ameritas Investment Partners Inc. lifted its holdings in shares of EXACT Sciences by 5.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 9,640 shares of the medical research company’s stock worth $341,000 after acquiring an additional 511 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of EXACT Sciences by 17.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock worth $144,000 after acquiring an additional 600 shares during the last quarter. Lincoln National Corp lifted its holdings in shares of EXACT Sciences by 7.8% during the 2nd quarter. Lincoln National Corp now owns 10,104 shares of the medical research company’s stock worth $357,000 after acquiring an additional 728 shares during the last quarter. Finally, Amalgamated Bank lifted its holdings in shares of EXACT Sciences by 6.0% during the 3rd quarter. Amalgamated Bank now owns 14,964 shares of the medical research company’s stock worth $705,000 after acquiring an additional 845 shares during the last quarter. 82.39% of the stock is owned by hedge funds and other institutional investors.

A number of research firms have recently issued reports on EXAS. Leerink Swann reaffirmed an “outperform” rating and set a $50.00 price objective (up from $45.00) on shares of EXACT Sciences in a report on Thursday, September 21st. BidaskClub raised shares of EXACT Sciences from a “hold” rating to a “buy” rating in a report on Thursday. Canaccord Genuity reaffirmed a “buy” rating and set a $60.00 price objective (up from $45.00) on shares of EXACT Sciences in a report on Tuesday, October 3rd. Zacks Investment Research raised shares of EXACT Sciences from a “hold” rating to a “buy” rating and set a $51.00 price objective for the company in a report on Tuesday, September 26th. Finally, Robert W. Baird reaffirmed a “buy” rating and set a $49.00 price objective on shares of EXACT Sciences in a report on Friday, October 6th. Eight investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $50.58.

In related news, insider Kevin T. Conroy sold 134,057 shares of EXACT Sciences stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $59.50, for a total value of $7,976,391.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Graham Peter Lidgard sold 81,025 shares of EXACT Sciences stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $47.16, for a total transaction of $3,821,139.00. Following the completion of the transaction, the insider now owns 366,519 shares in the company, valued at approximately $17,285,036.04. The disclosure for this sale can be found here. In the last quarter, insiders sold 595,396 shares of company stock worth $32,953,769. 4.00% of the stock is owned by corporate insiders.

EXACT Sciences Co. (EXAS) opened at $53.73 on Thursday. EXACT Sciences Co. has a 52-week low of $13.05 and a 52-week high of $63.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.34 and a quick ratio of 9.98.

EXACT Sciences (NASDAQ:EXAS) last issued its earnings results on Monday, October 30th. The medical research company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.07. The company had revenue of $72.60 million for the quarter, compared to analysts’ expectations of $65.03 million. EXACT Sciences had a negative net margin of 60.71% and a negative return on equity of 30.32%. The firm’s revenue was up 158.4% compared to the same quarter last year. During the same quarter last year, the company earned ($0.36) EPS. analysts expect that EXACT Sciences Co. will post -1.12 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.watchlistnews.com/cornerstone-capital-management-holdings-llc-has-1-99-million-holdings-in-exact-sciences-co-exas/1775534.html.

EXACT Sciences Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EXACT Sciences Co. (NASDAQ:EXAS).

Institutional Ownership by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.